Tezepelumab is a biologic for severe asthma that reduces exacerbations by blocking TSLP, a cytokine which drives T2 and non-T2 inflammatory pathways. This benefits more patients than biologics that target T2 alone. My SSC investigated why some patients receiving Tezepelumab still exacerbate, by comparing biomarkers at baseline and during attacks.
-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
Nicola Claire Hood Memorial Award 